Abstract
Autoantibodies to eight of the aminoacyl-transfer RNA synthetases—the most well-recognized of which is anti-histidyl (Jo-1)—have all been implicated in the pathogenesis of antisynthetase syndrome (AS). AS is characterized by varying degrees of interstitial lung disease, myositis, arthropathy, fever, Raynaud’s phenomenon, and mechanic’s hands, and the morbidity and mortality of the disease are usually linked to the pulmonary findings. The value of a lung biopsy in AS cannot be overemphasized, as it serves to describe the underlying etiology of the interstitial lung disease, guide therapy, and estimate prognosis. Muscle disease shares many clinical features of polymyositis, yet histologically, the inflammatory involvement resembles that of dermatomyositis. Because inflammatory arthritis mimics rheumatoid arthritis, AS should be considered in atypical cases. Corticosteroids are the mainstay of acute therapy, although treatment often requires immunosuppressant medications such as cyclophosphamide, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, or rituximab.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance
Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep. 2003;5(6):425–30.
Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56(9):3125–31.
Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep. 2008;10(4):333–40.
• Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60(7):2183–92. The authors address the prevalence of ILD in a large cohort of patients with anti–Jo-1 antibodies and describe various clinical characteristics of such patients. The authors also identify various chemokines that may help a clinician distinguish Jo-1–positive ILD patients from others with idiopathic pulmonary fibrosis or anti–signal recognition particle–related myositis.
Marder GS, Greenwald R. Antisynthetase syndrome. In: Kagen LJ, editor. The inflammatory myopathies. Humana Press; 2009. p. 191–206.
Fischer A, Swigris JJ, du Bois RM, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719–24.
Kalluri M, Sahn SA, Oddis CV, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest. 2009;135(6):1550–6.
Hirakata M, Suwa A, Nagai S, et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol. 1999;162(4):2315–20.
Betteride Z, Gunawardena H, North J, et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford). 2007;46(6):1005–8.
Hashish L, Trieu EP, Sadanandan P, et al. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome. Arthritis Rheum. 2005;52 Suppl 9:S312.
Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 1980;23(8):881–8.
Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):859–90.
Brouwer R, Hengstman GJD, Egberts WV, et al. Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001;60(2):116–23.
Selva-O’Callaghan A, Labrador-Horrillo M, Solans-Laque R, et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006;55(5):791–8.
Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol. 2000;12(6):475–81.
Howard OM, Dong HF, Yang D, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196(6):781–91.
Park SG, Kim HJ, Min YH, et al. Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response. Proc Natl Acad Sci USA. 2005;102(18):6356–61.
Soejima M, Kang EH, Gu X, et al. Role of innate immunity in a model of histidyl-tRNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum. 2011;63(2):479–487.
Miller FW, Waite KA, Biswas T, et al. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA. 1990;87(24):9933–7.
Nagaraju K, Raben N, Loeffler L, et al. Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA. 2000;97(16):9209–14.
Katsumata Y, Ridgway WM, Oriss T, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29(2–3):174–86.
Barbasso Helmers S, Englund P, Engström M, et al. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009;60(8):2524–30.
Ascherman DP, Oriss TB, Oddis CV, et al. Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol. 2002;169(12):7127–34.
Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum. 2007;56(8):2729–39.
Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000;68(4):472–8.
Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity. 2006;39(3):233–41.
Schmidt WA, Wetzel W, Friedländer R, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies—an evolving spectrum of disease manifestations. Clin Rheumatol. 2000;19(5):371–7.
Targoff IN, Trieu EP, Miller FW. Reaction of anti-OJ autoantobodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J Clin Invest. 1993;9:2556–64.
Mii S, Kobayashi R, Nakano T, et al. A histopathologic study of mechanic’s hands associated with dermatomyositis: a report of five cases. Int J Dermatol. 2009;48(11):1177–82.
Bachmeyer C, Tillie-Leblond I, Lacert A, et al. “Mechanic’s hands”: a misleading cutaneous sign of the antisynthetase syndrome. Br J Dermatol. 2007;156(1):192–4.
Mielnik P, Wiesik-Szewczyk E, Olesinska M, et al. Clinical features and prognosis of patients with idiopathic inflammatory myopathies and anti-Jo-1 antibodies. Autoimmunity. 2006;39(3):243–7.
Meyer O, Charlanne H, Cherin P, et al. Subluxing arthropathy: an unusual manifestation of the antisynthetase syndrome. Ann Rheum Dis. 2009;68(1):152–3.
Oddis CV, Medsger Jr TA, Cooperstein LA. A subluxing arthropathy associated with the anti-Jo-1 antibody in polymyositis/dermatomyositis. Arthritis Rheum. 1990;33(11):1640–5.
Mumm GE, McKown KM, et al. Antisynthetase syndrome presenting as rheumatoid-like polyarthritis. J Clin Rheumatol. 2010;16(7):307–12.
Morgenthau AS, Padilla ML. Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med. 2009;76(1):2–23.
Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38(5):383–92.
Váncsa A, Csípo I, Németh J, et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009;29(9):989–94. Epub 2009 Mar 6.
Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum. 1996;26(1):459–67.
Tillie-Leblond I, Wislez M, Valeyre D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax. 2008;63(1):53–9.
Guglielmi S, Merz TM, Gugger M, et al. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J. 2008;31(1):213–7.
Schnabel A, Reuter M, Biederer J, et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum. 2003;32(5):273–84.
• Ji SY, Zeng FQ, Guo Q, et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl). 2010;123(5):517–22. This article would help readers recognize some of the adverse prognostic factors that may be present in patients with ILD and inflammatory myopathy at the time of diagnosis, and in turn recognize the need for early intervention and more aggressive therapy when indicated.
Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182–5.
La Corte R, Lo Mo Naco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006;39(3):249–53.
Cassidy EA, Aggarwal R, Fertig N, et al. Non-Jo-1 Anti-synthetase autoantibodies are not specific for myositis and are associated with poor survival. Arthritis & Rheumatism Abstract Supplement 2010. Abstract 929.
Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology (Oxford). 2000;39(6):632–6.
Barbasso Helmers S, Maryam Fathi M, Lundber IE, et al. KL-6: A serological biomarker for interstitial lung disease and pulmonary function in patients with polymyositis and dermatomyositis. Arthritis & Rheumatism Abstract Supplement 2010. Abstract 924.
Chatterjee S, Farver C. Severe pulmonary hypertension in Anti-Jo-1 syndrome. Arthritis Care Res (Hoboken). 2010;62(3):425–9.
Handa T, Nagai S, Kawabata D, et al. Long-term clinical course of a patient with anti PL-12 antibody accompanied by interstitial pneumonia and severe pulmonary hypertension. Intern Med. 2005;44(4):319–25.
Fathi M. Interstitial lung disease in polymyositis and dermatomyositis. Stockholm: Karolinska Institutet; 2006.
Knoell KA, Hook M, Grice DP, et al. Dermatomyositis associated with bronchiolitis obliterans organizing pneumonia (BOOP). J Am Acad Dermatol. 1999;40(2 Pt 2):328–30.
Hervier B, Masseau A, Mussini JM, et al. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine. 2009;76(5):575–6.
Jankowska M, Butto B, Debska-Slizień A, et al. Beneficial effect of treatment with cyclosporin A in a case of refractory antisynthetase syndrome. Rheumatol Int. 2007;27(8):775–80.
Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439–46.
Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201–6.
Vandenbroucke E, Grutters JC, Altenburg J, et al. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int. 2009;29(12):1499–502.
Brulhart L, Waldburger JM, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis. 2006;65(7):974–5.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Katzap, E., Barilla-LaBarca, ML. & Marder, G. Antisynthetase Syndrome. Curr Rheumatol Rep 13, 175–181 (2011). https://doi.org/10.1007/s11926-011-0176-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11926-011-0176-8